GlassScriptPhysician profile
Laura B Butz
NPI 1538452404
$44,209.17
in general payments reported to CMS, 2019-2025
63 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,465 · 2020: $1,349 · 2021: $1,322 · 2022: $2,610 · 2023: $2,852 · 2024: $1,736 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $25K · Food and Beverage: $8,482 · Travel and Lodging: $2,114 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $24,850.00 |
| Food and Beverage | $8,481.63 |
| Travel and Lodging | $2,113.51 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $29,347.47 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $1,237.73 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $1,224.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,172.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $913.29 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $902.03 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $817.72 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $633.42 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $626.58 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $528.00 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $394.41 | 2019-2025 | Unithroid |
| Abbvie INC. | $371.80 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $369.72 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.52 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $345.43 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $338.30 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $318.75 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.28 | 2019-2024 | Cycloset |
| Beta Bionics, INC. | $300.75 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $293.56 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $255.28 | 2019-2025 | |
| Amarin Pharma, INC. | $210.51 | 2019-2023 | |
| Sequel Med Tech, LLC | $198.12 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $173.70 | 2019-2020 | |
| Ibsa Pharma INC. | $170.99 | 2021-2025 | Tirosint, Licart, Licart |
| Alexion Pharmaceuticals, INC. | $170.37 | 2020-2025 | Strensiq |
| Cequr Corporation | $161.18 | 2023-2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $158.15 | 2024-2025 | |
| Lifescan, INC. | $141.01 | 2019-2023 | |
| Endo USA, INC. | $118.36 | 2024-2025 | Aveed |
| Endo Pharmaceuticals INC. | $98.73 | 2019-2024 | Aveed |
| Merck Sharp & Dohme LLC | $96.28 | 2019-2023 | Segluromet, Steglujan, Steglatro |
| Almatica Pharma LLC | $94.61 | 2024-2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $87.82 | 2021-2024 | Crysvita |
| Medtronic, INC. | $77.35 | 2022-2025 | Inceptiv, Minimed 780g |
| Ipsen Biopharmaceuticals, INC | $74.25 | 2020 | |
| Kyowa Kirin, INC. | $73.20 | 2023-2025 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $71.68 | 2021-2023 | Livalo, Seglentis |
| Ascendis Pharma Endocrinology INC | $65.01 | 2025 | Yorvipath |
| Mannkind Corporation | $64.55 | 2019-2021 | |
| Zealand Pharma US, INC. | $63.19 | 2021 | |
| Amryt Pharma Holdings LTD | $58.99 | 2021-2023 | Mycapssa |
| Sandoz INC. | $54.79 | 2025 | Jubbonti |
| Regeneron Healthcare Solutions, INC. | $52.16 | 2019 | |
| Shire North American Group INC | $51.29 | 2019 | |
| Esperion Therapeutics, INC. | $49.89 | 2021-2024 | Nexletol |
| Chiesi USA, INC. | $41.72 | 2025 | Mycapssa, Myalept |
| Madrigal Pharmaceuticals | $40.59 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $39.58 | 2023-2025 | Imcivree, Imcivree |
| Recordati_rare_diseases_inc. | $39.02 | 2023-2025 | Isturisa, Signifor Lar |
| Amphastar Pharmaceuticals, INC. | $37.04 | 2024-2025 | |
| Medtronic Minimed, INC. | $36.90 | 2019-2020 | |
| Halozyme INC | $35.66 | 2023 | |
| Ascensia Diabetes Care US INC. | $32.51 | 2025 | |
| Avvisto Therapeutics, LLC | $31.58 | 2025 | Cycloset |
| Horizon Therapeutics Plc | $30.08 | 2022-2023 | Tepezza |
| Tolmar, INC. | $29.13 | 2023-2025 | Jatenzo |
| Becton, Dickinson and Company | $26.45 | 2022 | |
| Companion Medical, INC. | $22.67 | 2019 | |
| Renalytix Ai, INC. | $20.15 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Opko Pharmaceuticals, LLC | $17.19 | 2024 | Rayaldee |
| Eisai INC. | $16.74 | 2025 | |
| Rgh Enterprises LLC | $16.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Butz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.